Walleye Capital LLC Buys 15,971 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Walleye Capital LLC grew its stake in Nkarta, Inc. (NASDAQ:NKTXGet Rating) by 53.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,083 shares of the company’s stock after acquiring an additional 15,971 shares during the quarter. Walleye Capital LLC’s holdings in Nkarta were worth $524,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of NKTX. Northern Trust Corp increased its stake in Nkarta by 2.0% during the 4th quarter. Northern Trust Corp now owns 148,984 shares of the company’s stock worth $2,287,000 after purchasing an additional 2,883 shares in the last quarter. TD Asset Management Inc. bought a new stake in Nkarta during the 4th quarter worth approximately $564,000. Ensign Peak Advisors Inc increased its stake in Nkarta by 22.4% during the 4th quarter. Ensign Peak Advisors Inc now owns 48,356 shares of the company’s stock worth $743,000 after purchasing an additional 8,840 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Nkarta during the 4th quarter worth approximately $288,000. Finally, Deep Track Capital LP bought a new stake in Nkarta during the 4th quarter worth approximately $19,409,000.

Insider Activity at Nkarta

In other Nkarta news, insider Ralph Brandenberger sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $13.41, for a total transaction of $40,230.00. Following the transaction, the insider now owns 7,800 shares of the company’s stock, valued at $104,598. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Ralph Brandenberger sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $13.41, for a total value of $40,230.00. Following the completion of the sale, the insider now directly owns 7,800 shares of the company’s stock, valued at $104,598. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James Trager sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $17.53, for a total value of $87,650.00. Following the transaction, the insider now directly owns 62,172 shares in the company, valued at $1,089,875.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,593 shares of company stock worth $307,687. Insiders own 5.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NKTX. Needham & Company LLC began coverage on Nkarta in a research note on Thursday, July 28th. They set a “buy” rating and a $26.00 target price for the company. Cantor Fitzgerald lowered their target price on Nkarta from $60.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, August 12th. Finally, SVB Leerink started coverage on Nkarta in a research report on Monday, July 18th. They set an “outperform” rating and a $30.00 price target for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nkarta presently has an average rating of “Buy” and an average target price of $39.63.

Nkarta Stock Up 1.7 %

Shares of Nkarta stock opened at $12.50 on Thursday. Nkarta, Inc. has a 12-month low of $7.55 and a 12-month high of $31.45. The business’s 50 day moving average is $14.60 and its 200-day moving average is $13.34. The stock has a market cap of $608.21 million, a P/E ratio of -4.51 and a beta of 0.07.

Nkarta (NASDAQ:NKTXGet Rating) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. On average, sell-side analysts expect that Nkarta, Inc. will post -2.57 EPS for the current year.

Nkarta Profile

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Featured Articles

Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTXGet Rating).

Institutional Ownership by Quarter for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.